16 results about "Graft survival" patented technology

The present invention addresses the problem of providing: a method for preparing hepatic lineage cells in a large amount and with high purity; and a method for preparing liver system cells which can achieve high graft survival rate in a living body.　The present invention provides: a hepatoblast proliferation promoter and a culture medium, each of which contains a ROCK inhibitor, a TGFβ signaling pathway inhibitor, a Wnt signaling pathway activator, and a growth factor; and a proliferation / culture method using the hepatoblast proliferation promoter or the culture medium.

A B cell maturation antigen (BCMA) is expressed on plasma cells. The present invention provides methods of desensitizing a patient in need of solid organ transplantation against HLA antibodies using bispecific antibodies that bind to both BCMA and CD3 and activate T cells by the CD3 complex in the presence of plasma cells expressing BCMA. In certain embodiments, the bispecific antibodies of the invention reduce alloantibody levels and / or reduce computational population reactive antibody levels to promote solid organ transplantation and / or improve long term graft survival and / or function.

The fixing device comprises a grafting cylinder and a fixing seat, an inserting groove is formed in the fixing seat, an inserting plate is arranged at the bottom of the grafting cylinder, the inserting plate is movably inserted into the inserting groove, a first opening is formed in the bottom of the grafting cylinder, a drainage hole is formed in one side of the bottom of the grafting cylinder, and a second opening is formed in the other side of the bottom of the grafting cylinder. A first opening is formed in the top of the fixing seat, a second opening corresponding to the first opening is formed in the top of the fixing seat, a water collecting cavity is formed in the fixing seat, a first through hole matched with the drainage hole is formed in one side of the top of the fixing seat, the first through hole is communicated with the water collecting cavity, and a fixing mechanism is fixedly installed at the bottom end of the fixing seat. The grafting device has the advantages that the drainage hole is aligned with the first through hole by rotating the grafting cylinder, accumulated water in the grafting cylinder can be drained into the water collecting cavity, then the drainage hole and the first through hole are staggered by rotating the grafting cylinder, a large amount of accumulated water is prevented from being accumulated in the grafting cylinder, bacterium breeding is effectively avoided, and the grafting survival rate is increased.

The invention relates to the field of biological medicine, in particular to a retina organ with a vision improving function and a preparation method and application thereof. According to the method, the bottleneck in the prior art is broken through through innovative integration of low-intensity ultrasonic stimulation and a retina organoid technology, the advantages of efficiently accelerating differentiation and maturation of the photoreceptor and improving the differentiation efficiency of the photoreceptor are achieved, meanwhile, the bottleneck of transplantation integration is broken through, survival and integration of the graft are improved, and the purpose of recovering vision is achieved. In conclusion, the retina organoid culture method capable of promoting differentiation of the photoreceptor through ultrasonic stimulation is constructed for the first time, and a new view angle can be provided for research on treatment of retina degenerative diseases. Meanwhile, the core bottlenecks of insufficient photoreceptor differentiation and low transplantation integration rate of the retinal organ are solved, the retinal organ subjected to low-intensity ultrasonic stimulation can be used as a high-quality graft source, and a novel treatment strategy is provided for retinal degenerative diseases.

B-cell maturation antigen (BCMA) is expressed on plasma cells. The present invention provides methods for desensitizing patients in need of a solid organ transplant to anti-HLA antibodies using bispecific antibodies that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing plasma cells. In certain embodiments, the bispecific antibodies of the present invention reduce alloantibody levels and / or reduce calculated panel reactive antibody levels to facilitate solid organ transplantation and / or improve long term graft survival and / or function.

Provided herein are genetically modified organs and / or tissues comprising an immunosensor transgene, methods of generating thereof by combining genetic engineering methods with ex vivo machine perfusion, and methods of use thereof by transplantation. In some embodiments, it includes improving postoperative outcomes by genetically modifying donor organs to express diagnostic markers for rejection or infection and / or therapeutic constructs for improving graft survival.

The invention provides a fat transplantation survival rate prediction system based on transfer learning and biomechanical simulation. Comprising an image data acquisition module, a fat distribution density prediction module, a cell integrity information acquisition module, a cell survival rate prediction module, a temperature image acquisition module, a blood supply state prediction module, a model fusion module, a transfer learning module and a survival rate output module. According to the system, by integrating multi-source data of preoperative MRI images, intraoperative pressure sensing and postoperative infrared thermal imaging, three prediction models of fat distribution density, cell survival rate and blood supply state are established and fused, animal experiment data knowledge is migrated to a human body for application in combination with a transfer learning technology, accurate prediction of the survival rate after fat transplantation is achieved, and the survival rate of fat transplantation is accurately predicted. The prediction accuracy rate reaches 85% or above, and scientific decision support is provided for clinic.

The disclosure provides a method for treating and / or preventing graft rejection with A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMT S13). The disclosure provides a method for increasing ADAMTS13-mediated von Willebrand factor (VWF) cleavage in a subject that received a graft by administering ADAMTS13. The disclosure also provides a method of determining the likelihood that a subject will rejection a graft.

The invention discloses a stem grafting method which comprises the following steps: step 1, processing a grafting position, trimming the grafting position to keep the end face of the grafting position flat, inserting the grafting position into the lower end of a shell, rotating a handle, and clamping and fixing a branch at the grafting position by a first fixing piece; step 2, processing before grafting: inserting the lower end of the branch to be grafted into the shell from top to bottom, and inserting the lower end of the branch to be grafted into the second fixing piece, when the technical scheme is implemented, a user only needs to operate according to steps to complete grafting operation, the user does not need to have grafting experience, and the grafting efficiency is improved. The method is suitable for large-scale grafting operation, the grafting efficiency is improved, the grafting process is more standard, and the grafting survival rate is increased.

The utility model discloses a grafting knife device for magnolia grafting belongs to grafting knife technical field, the device includes handle and blade, is equipped with the medicine storage jar, spray pump and battery and button on handle, and spray pump is connected with spray head through spray pipe, and the blade is connected with the limiting block, and the spray head is connected with the limiting block. The utility model integrates the cutting function of cutter and the spraying function of protective liquid, and the operator can spray the protective liquid immediately after completing the cutting action, forms the protective layer at the cutting surface, thereby effectively slows down the oxidation process, improves the tissue healing rate between the scion and the stock, and significantly improves the grafting survival rate. The structure is compact, the operation is simple, and it is suitable for field operation or nursery use. Compared with the traditional spraying treatment mode, spraying is more timely. The spray head can switch work on both sides of the blade. The left and right switching not only meets the spraying needs of the inner and outer sides of the grafting knife, but also can adapt to both hands when holding the grafting knife, greatly facilitating the operator to use.

This invention provides an engineered platelet and its application in the preparation of anti-injury drugs for liver transplantation. This engineered platelet utilizes the natural liver tropism of platelets; upon reaching the site of liver injury, PLT-aCCL2 is specifically activated under local microenvironment stimulation, releasing loaded small-sized antibody fragments or active ingredients. This effectively penetrates deep into the liver parenchyma, overcoming the problem of poor tissue penetration of large-molecule protein drugs. Through this targeted delivery strategy, aCCL2 can efficiently and specifically block the physiological function of the chemokine CCL2, inhibiting the infiltration of peripheral monocytes into the liver, thereby blocking the initiation and amplification of the inflammatory cascade. Ultimately, this strategy significantly inhibits T-cell-mediated adaptive immune responses and acute rejection, effectively reducing graft injury and prolonging graft survival.

The embodiments of the present invention disclose a periosteal material for promoting local endogenous bone regeneration and repair, and a preparation method thereof. The method comprises: dissolving GelMA in PBS to obtain a GelMA solution; adding a photoinitiator, HAAMMA, and E7 peptide to the GelMA solution, and conducting a free radical polymerization reaction under ultraviolet light to obtain a polymer product; washing the polymer product, freeze-drying, and sterilizing to obtain the periosteal material; wherein the HAAMMA is MA-modified HAAM. The present invention provides a bone tissue engineering membrane material prepared using GelMA, HAAM, and E7 peptide as raw materials, which can promote both stem cell recruitment and osteoblast differentiation into bone in the bone defect area, i.e., a biomimetic periosteal material with osteogenesis-promoting function, to address the problems of poor graft survival, healing, and slow healing after bone transplantation in large bone defects.

The application provides a high grafting crown changing method for Lecythis minor, which comprises the following steps of germplasm resource screening, scion treatment, mother stock cutting, grafting, stock removal from shade and post-grafting management, has high grafting survival rate and stock survival rate, short healing time and nursery time, and the scion is intact without damage, no dry burst, the stock survival rate is 95.2-97.2%, and the grafting survival rate is 95.2-98.4%.

The application discloses a grafting method for south-chuan-microcos paniculata, belongs to the grafting technical field of south-chuan-microcos paniculata, and grafts the south-chuan-microcos paniculata through the steps of rootstock selection and treatment, scion selection and treatment, grafting, binding, post-grafting management and the like, and coats the prepared healing accelerator at the grafting joint, so that the components in the healing accelerator jointly act, the influence of various adverse factors on the grafting survival rate is reduced, the grafting survival rate of the south-chuan-microcos paniculata is improved, and the problem of low grafting survival rate of the south-chuan-microcos paniculata is solved.

The present disclosure provides, in part, combination therapies and methods of eliciting immuno-tolerance using PDL1 variants and immune system modulators.

The invention discloses a method for coping with rejection reaction of a graft acceptor to a graft. Methods of extending graft survival in a transplant recipient, extending survival in a recipient, delaying and / or inhibiting a delay of implant function in a recipient, and / or reducing the amount of an immunosuppressive agent for transplantation. The disclosed methods include providing a graft with CHP or a pharmaceutically acceptable salt thereof. A method of preparing a pharmaceutical composition for treating a graft to modulate graft survival in a graft recipient is also provided.